Another Phase II clinical trial study (NCT01720875) showed that despite observed toxicity and dose reductions, which demonstrated that the combination of vorinostat, bortezomib, and dexamethasone was effective and had good response rates in relapsed myeloma, suggesting further optimization of HDAC inhibitor-based combination therapy for myeloid Tumor to improve tolerance and enhance efficacy [88]. The gene discussed is HDAC9; the disease is plasma cell myeloma.